NEW YORK CITY, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ:EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Exelixis and certain of its officers and/or directors […]
NEW YORK CITY, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ:PRAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Praxis and certain of its officers
NEW YORK CITY, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Albany International Corp. ("Albany" or the "Company") (NYSE:AIN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Albany and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Insperity, Inc. ("Insperity" or the "Company") (NYSE:NSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Insperity and certain of its officers and/or directors
NEW YORK CITY, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of agilon health, Inc. ("agilon" or the "Company") (NYSE:AGL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether agilon and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Marex Group PLC ("Marex" or the "Company") (NASDAQ:MRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Marex and certain of its officers and/or
NEW YORK, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Innovative Solutions and Support, Inc.("IS&S" or the "Company") (NASDAQ:ISSC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether IS&S and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Soleno and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Valneva and certain of its officers and/or directors
NEW YORK, NY / ACCESS Newswire / September 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. ("Semler" or the "Company") (NASDAQ:SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged